Aktie A2DF26 AXIM BIOTECHNOLOGIES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen AXIM Biotechnologies, Inc.

Aktien

A2DF26

US05463V1008

AXIM

Markt geschlossen - OTC Markets
Andere Börsenplätze
 21:56:54 02.05.2024 		% 5 Tage % 1. Jan.
0,0122 USD -18,67 % Intraday Chart für AXIM Biotechnologies, Inc. +11,93 % -35,79 %
16.04. AXIM Biotechnologies, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
20.02. AXIM Biotechnologies, Inc. Tränenbasierte Testplattform gewinnt nach erfolgreicher klinischer Validierung weiter an Zugkraft CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
AXIM Biotechnologies, Inc. announced that it expects to receive $0.75 million in funding from Medical Marijuana, Inc.
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
AXIM Biotechnologies - Optometric Management, Perform a Pre-Fit Ocular Surface Evaluation
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AXIM Biotechnologies, Inc. announced that it has received $20 million in funding
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DF26 Aktie
  4. Nachrichten AXIM Biotechnologies, Inc.
  5. Andere Sprachen